These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15317592)

  • 1. Noncytotoxic ribonuclease, RNase T1, induces tumor cell death via hemagglutinating virus of Japan envelope vector.
    Yuki S; Kondo Y; Kato F; Kato M; Matsuo N
    Eur J Biochem; 2004 Sep; 271(17):3567-72. PubMed ID: 15317592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of HVJ envelope vector and its application to gene therapy.
    Kaneda Y; Yamamoto S; Nakajima T
    Adv Genet; 2005; 53():307-32. PubMed ID: 16240999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system.
    Kaneda Y; Nakajima T; Nishikawa T; Yamamoto S; Ikegami H; Suzuki N; Nakamura H; Morishita R; Kotani H
    Mol Ther; 2002 Aug; 6(2):219-26. PubMed ID: 12161188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel method of non-viral efficient gene transfer into neonatal cardiac myocytes.
    Tashiro H; Aoki M; Isobe M; Hashiya N; Makino H; Kaneda Y; Ogihara T; Morishita R
    J Mol Cell Cardiol; 2005 Sep; 39(3):503-9. PubMed ID: 16040050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a transferrin receptor-targeting HVJ-E vector.
    Shimbo T; Kawachi M; Saga K; Fujita H; Yamazaki T; Tamai K; Kaneda Y
    Biochem Biophys Res Commun; 2007 Dec; 364(3):423-8. PubMed ID: 17961511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of tissue-targeting hemagglutinating virus of Japan envelope vector for successful delivery of therapeutic gene to mouse skin.
    Kawachi M; Tamai K; Saga K; Yamazaki T; Fujita H; Shimbo T; Kikuchi Y; Nimura K; Nishifuji K; Amagai M; Uitto J; Kaneda Y
    Hum Gene Ther; 2007 Oct; 18(10):881-94. PubMed ID: 17892442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems.
    Kaneda Y
    Expert Opin Drug Deliv; 2008 Feb; 5(2):221-33. PubMed ID: 18248320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector.
    Mima H; Tomoshige R; Kanamori T; Tabata Y; Yamamoto S; Ito S; Tamai K; Kaneda Y
    J Gene Med; 2005 Jul; 7(7):888-97. PubMed ID: 15712245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HVJ liposomes and HVJ envelope vectors.
    Kaneda Y
    Cold Spring Harb Protoc; 2011 Oct; 2011(10):1281-9. PubMed ID: 21969614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New vector innovation for drug delivery: development of fusigenic non-viral particles.
    Kaneda Y
    Curr Drug Targets; 2003 Nov; 4(8):599-602. PubMed ID: 14577648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.
    Ito M; Yamamoto S; Nimura K; Hiraoka K; Tamai K; Kaneda Y
    J Gene Med; 2005 Aug; 7(8):1044-52. PubMed ID: 15756713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector.
    Morishita N; Nakagami H; Morishita R; Takeda S; Mishima F; Terazono B; Nishijima S; Kaneda Y; Tanaka N
    Biochem Biophys Res Commun; 2005 Sep; 334(4):1121-6. PubMed ID: 16134237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient in vivo delivery of plasmids and oligonucleotides using hemagglutinating virus of Japan envelope (HVJ-E) vector in immunological disease models.
    Kitani A; Fichtner-Feigl S
    Curr Protoc Immunol; 2010 Nov; Chapter 10():Unit 10.17E.1-9. PubMed ID: 21053301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HVJ-envelope as an innovative vector system for cardiovascular disease.
    Kotani H; Nakajima T; Lai S; Morishita R; Kaneda Y
    Curr Gene Ther; 2004 Jun; 4(2):183-94. PubMed ID: 15180584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-replicating oncolytic vector as a novel therapeutic tool against cancer.
    Kaneda Y
    BMB Rep; 2010 Dec; 43(12):773-80. PubMed ID: 21189152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid transport of plasmid DNA into the nucleolus via actin depolymerization using the HVJ envelope vector.
    Suvanasuthi S; Tamai K; Kaneda Y
    J Gene Med; 2007 Jan; 9(1):55-62. PubMed ID: 17149789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth.
    Lee CH; Nishikawa T; Kaneda Y
    Oncotarget; 2017 May; 8(21):35048-35060. PubMed ID: 28456782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HVJ Envelope Vector and Its Application to Gene Therapy.
    Kaneda Y; Yamamoto S; Nakajima T
    Adv Genet; 2005; 53PA():307-332. PubMed ID: 16243069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HVJ-E/importin-β hybrid vector for overcoming cytoplasmic and nuclear membranes as double barrier for non-viral gene delivery.
    Kawazu T; Kanzaki H; Uno A; Azuma H; Nagasaki T
    Biomed Pharmacother; 2012 Oct; 66(7):519-24. PubMed ID: 22727893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope.
    Matsuda M; Yamamoto T; Matsumura A; Kaneda Y
    Gene Ther; 2009 Dec; 16(12):1465-76. PubMed ID: 19675593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.